Taken together, these results indicate CTGF-expressing tumor cells are sensitive to TNFR1, IκB and CTGF-targeted therapies and suggest resveratrol may be effective means of targeting CTGF-expressing cell populations to impede the EMT-inducing CSC-like and metastatic phenotypes. Here, CCN2 is linked to neoplasm.